Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time...
Biolevate to Advance AI-Native Life Sciences Workflows With NVIDIA BioNeMo Agent ToolkitBiolevate is integrating NVIDIA BioNeMo Recipes, agentic AI components...
Biolevate to Advance AI-Native Life Sciences Workflows With NVIDIA BioNeMo Agent ToolkitBiolevate is integrating NVIDIA BioNeMo Recipes, agentic AI components...
AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) gradually strips people of command over...
Global AI in Healthcare Market Expected to Expand at 38.90% CAGR from 2026 to 2033 as Healthcare Systems Embrace Predictive...
In this free webinar, gain insight into how patient identification approaches can improve study efficiency in precision neurology programs. Attendees...
The partnership will create one of the most detailed real-world datasets from a large independent GI practice to accelerate drug...
NDA submission supported by positive Phase 3 data recently published in JAMA Neurology.Ecopipam is a first-in-class selective dopamine D1 receptor...
Filing acceptance based on data from the phase III SUNMO study where subcutaneous Lunsumio VELO plus Polivy demonstrated a 59%...
SACRAMENTO, Calif., June 17, 2026 /PRNewswire/ -- Fellow Shareholders,Over the past several months, Lunai Bioworks (NASDAQ: LNAI) has continued to...
SACRAMENTO, Calif., June 17, 2026 /PRNewswire/ -- Fellow Shareholders,Over the past several months, Lunai Bioworks (NASDAQ: LNAI) has continued to...
Aarhus, Denmark, 17 June 2026 – NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore...
DALLAS, June 16, 2026 /PRNewswire/ -- WeInfuse, the premier software platform for infusion providers and specialty pharmacies, announced a strategic...
Fingerpaint Marketing adds a proven commercial leader with deep expertise across the industry's most complex therapeutic categories.CEDAR KNOLLS, N.J., June...
The new 'virtual biopsy' model predicts brain activity, therapy response, and side effects in patients with up to 3x greater...
Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with...
Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building...
High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not...
Key Highlights Record revenue, continued momentum: all-time high $65.3M in FY2025; strongest-ever Q1 2026, carrying into Q2.Record operational momentum: CosmoFarm...
Health Canada Priority Review targets an expedited 180-day review period for givinostat, reflecting Italfarmaco’s commitment to Canadian DMD communityNDS is...